Article Text

Randomised controlled trial
In two parallel pragmatic equivalence trials, leukotriene receptor antagonists as initial therapy for asthma compared with inhaled corticosteroids and as add on therapy to ICS compared with adding long-acting β agonists provided equivalent short-term asthma quality of life but were associated with more medication switches
  1. J Mark FitzGerald
  1. Centre for Lung Health, Institute for Heart and Lung Health, University of British Columbia, Canada
  1. Correspondence to J Mark FitzGerald
    Centre for Lung Health, Institute for Heart and Lung Health, University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z1M9, Canada; mark.fitzgerald{at}

Statistics from

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Asthma is a common condition for which there are robust evidence-based guidelines.1 Such guidelines are by definition based on the gold standard of randomised controlled trials (RCTs) which often have restrictive, inclusion and exclusion criteria, such that patients enrolled are not representative of patients seen in real world settings. Pragmatic trial designs have been suggested as a method of overcoming some of these limitations.2


In two parallel, multicentre open-labelled pragmatic trials, Price and colleagues evaluated the effectiveness of inhaled corticosteroids (ICS) versus leukotriene receptor antagonists (LTRAs) as initial asthma therapy (in trial 1) and the addition of an LTRA or a long-acting β agonist (LABA), by random allocation, for participants who remained uncontrolled after 12 weeks of ICS (in trail 2). Participants with physician-diagnosed asthma were recruited from 53 primary care practices in the UK. The study was not funded by the …

View Full Text

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.